Advertisement
Celecoxib is noninferior to naproxen and ibuprofen in cardiac safety
Pioneer of angioplasty never stopped innovating and teaching
Dr. Steven Nissen shares why these studies matter
A veteran academic research organization finds its mission more critical than ever
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Also finds PCSK9 inhibitor more potent than ezetimibe in statin-intolerant patients
Trial stopped early after evacetrapib fails to budge event rate
Not all coronary calcium is the same, analysis shows
New Scientific Statement From ADA & AHA Says It Should Be Considered Sooner For Obese Patients
A checklist of the latest evidence to share with patients
How it fits into today’s cholesterol-lowering practice
Advertisement
Advertisement